Michael Liang, Ph.D.
Michael Liang joined Baird Capital in 2006 and concentrates on healthcare investments. Prior to joining Baird Capital, Mike was a venture investor with Advent Venture Partners and before that, served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike is currently a member of the board of directors of Amphora Medical, GenomeDx Biosciences, Insightra Medical, Veniti, and Zurex Pharma, serving as Chairman of the Board for Insightra Medical and Veniti. He was previously a board member of Interlace Medical before its acquisition in 2011 and a board observer of TomoTherapy before its public offering. Mike is a member of the advisory board for the University of Illinois Chicago’s Proof of Concept Fund, Northwestern University’s Innovation and New Ventures Office, the Wisconsin Alumni Research Foundation (WARF) Accelerator program, and the governance board for the Chicago Biocenter initiative. Mike also is a member of Rush University Medical Center’s Associates Board. Mike received a BS from the University of California Berkeley, a Ph.D. in biophysical chemistry from Stanford University and conducted a postdoctoral fellowship at Harvard University.